Bone Marrow Versus Adipose Tissue as a Cell Source for Infiltrative Treatment of Knee Osteoarthritis
Condition(s) studied
Investigational drug(s) / intervention(s)
Bone marrow aspirate concentrate injection: single intra-articular injection of Bone Marrow aspirate concentrate derived from the patient's iliac crest
intra-articular injection of Minimally manipulated adipose tissue: single intra-articular injection of Minimally manipulated adipose tissue derived from the patient's abdominal adipose tissue
Study summary
The MAST-GR study is a randomized controlled interventional trial with parallel treatment arms and 1:1 allocation
The primary objective of the study is to compare the safety and efficacy of a single intra-articular infiltration of Bone marrow aspirate concentrate (BMAC) with one of minimally manipulated adipose tissue (MM-AT) so as to determine the most effective cellular product in treating patients with knee osteoarthritis (OA).
The secondary objective is to demonstrate whether intra-articular infiltration of BMAC or MM-AT can induce disease-modifying effects in knee OA by imaging and biological assessments on peripheral blood.
The tertiary objective of the study is to identify factors that influence the clinical response to treatment (baseline characteristics of patients, biological characteristics of the treated knee, characteristics of cellular products, BMAC and MM-AT).
Eligibility
Primary outcome measure(s)
- Western Ontario and McMaster University Osteoarthritis index (WOMAC) - Pain subscale — 6 months follow-up
It is a pathology-specific questionnaire used for the assessment of referred pain at the knee joint level in patients with OA
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Istituto Ortopedico Rizzoli | Bologna | Italy | Recruiting |
More Istituto Ortopedico Rizzoli trials in Italy
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT06040957 on ClinicalTrials.gov ↗ ← All trials in Italy